Søgning
Søgning på udtrykket 'paxlovid' giver 10 resultater
Dokumenter [1]
Nyt fra tidsskrifterne [5]
Aktuelle smitsomme sygdomme [4]
Denne vejledning er tiltænkt diagnostik og behandling af COVID-19. Denne retningslinje vil løbende blive opdateret, som ny evidens kommer frem.
Ændringer siden version 29:
Indikationer for COVID-19 test er tilføjet.
Nyt fra tidsskrifterne [5]
BMC Infectious Diseases
26.11.2024
. Abstract. . Background. Paxlovid is one of the most effective antiviral therapies for COVID-19 patients, but no studies have explored the efficacy predictors of this drug. . . . Methods. To investigate whether D-dimer could be used as a predictor of paxlovid response.
Journal of the American Medical Association
6.10.2024
This Medical News article discusses the latest research about the use of nirmatrelvir-ritonavir, sold as Paxlovid, to treat COVID-19 and, possibly, to prevent or treat long COVID.
BMC Infectious Diseases
6.08.2024
. Abstract. . Purpose. In this study, we aim to explore the efficacy of paxlovid on reducing mortality of COVID-19 patients in clinical setting, especially whether paxlovid modifies the risk of death in these severe and critical patients. . . . Methods.
Journal of the American Medical Association
21.02.2024
This Medical News story examines the latest information about rebound, treatment eligibility, optimal dosing, and other questions related to nirmatrelvir-ritonavir for treating COVID-19.
Clinical Infectious Diseases
18.12.2024
Abstract . Background . PAXLOVID consists of nirmatrelvir, an inhibitor of SARS-CoV-2 main protease (Mpro), copackaged with ritonavir, a pharmacokinetic enhancer. Nirmatrelvir/ritonavir received emergency use authorization in the United States in 2021 and was approved in 2023. However, there is limited published information on SARS-CoV-2 clinical resistance to nirmatrelvir/ritonavir.Methods .
Aktuelle smitsomme sygdomme [4]
Aktuelle smitsomme sygdomme [4]
Medscape Infectious Diseases
1.02.2025
New research showed some long COVID patients get symptom relief by taking an extended course of Paxlovid. Data are preliminary but promising. . Medscape Medical News
Medscape Infectious Diseases
29.07.2024
With no standard approved long COVID therapies, research turns to a proven COVID drug and other 'low-risk, high-reward' help. . Medscape Medical News
Medscape Infectious Diseases
5.04.2024
Clinicians should still consider prescribing the drug to adults over age 65 or those who are immunocompromised, experts said. . Medscape Medical News
Medscape Infectious Diseases
1.01.2025
Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol Myers Squibb's cancer cell therapies and. . Reuters Health Information